study question: Is decorin (DCN), a putative modulator of growth factor (GF) signaling, expressed in the primate ovary and does it play a role in ovarian biology?
Introduction
The adult ovary is a dynamic organ, in which constant growth and regression of follicles, plus formation and regression of the corpus luteum (CL), require a constantly adapting extracellular matrix (ECM). The ECM of the ovary consists of basal laminae (BL), interstitial ECM and intra-epithelial matrix (focimatrix), i.e. plaques of aggregates between granulosa cells (GCs) of ovarian follicles (Irving-Rodgers et al., 2010) .
While information about the ovarian ECM in rodent and bovine species is growing (Irving-Rodgers et al., 2010) , little is known about ECM components in the human or non-human primate ovary (Irving-Rodgers et al., 2006; Ricciardelli and Rodgers, 2006) . Collagen type IV, laminins and the proteoglycan versican were reported to be part of the ECM of the human CL (Irving-Rodgers et al., 2006 ). This study also described ECM in the form of sub-endothelial BL and aggregates of interstitial ECM between luteal cells that lack a continuous BL. Interestingly, laminins and collagen type IV are synthesized by luteal cells, implying an active role of endocrine cells in the formation of the ECM. Studies also indicated that other non-collagenous proteins, including the proteoglycan decorin (DCN) (Ricciardelli and Rodgers, 2006; Grisaru et al., 2007) , are present in the ECM of normal and tumorous tissues in human ovaries. Its expression in normal ovarian tissue, namely in extracts of bovine follicles, that include the ovarian stroma and tunica albuginea (McArthur et al., 2000; Ricciardelli and Rodgers, 2006) further indicates that DCN is a component of the ovarian ECM. Whether DCN is expressed by follicular GCs or theca cells, secreted into the follicular fluid (FF) or is present in the CL is not known at present.
DCN is a small leucine-rich proteoglycan associated with the ECM, especially with collagen type I, and has a widespread distribution in the human body (Iozzo and Schaefer, 2010) . It was found in human and monkey testes, while interestingly only trace amounts of DCN were detectable in the mouse testis (Ungefroren et al., 1995; Adam et al., 2011 Adam et al., , 2012 . DCN is remarkable in that it can interfere with the signaling of growth factors (GFs; Santra et al., 2002) . Two types of interaction can occur, including binding and storage of soluble GFs, thereby reducing the levels available for receptor binding and activation. In addition, DCN can bind to many GF receptors (GFRs), for example the epidermal GFR (EGFR; Iozzo et al., 1999; Iozzo and Schaefer, 2010) . The binding causes phosphorylation and activation of EGFR and can be followed by internalization and down-regulation of EGFR signaling, resulting in a chronic blockage of EGF/EGFR actions (Csordas et al., 2000; Zhu et al., 2005; Adam et al., 2011) . This may be relevant to the regulation of the immature primate testis and in states of human male infertility. In both of these situations, DCN is massively increased and may interfere with paracrine signaling of GFs (Adam et al., 2011 (Adam et al., , 2012 ).
In the ovary, especially of non-primate species, paracrine signaling via the EGFR and EGF-like molecules is known to be of importance. Recently studies in primate species, including the human, suggest a similar role (Inoue et al., 2009; Peluffo et al., 2012; Yu et al., 2012) . LH surge causes local production of EGF-like molecules, especially amphiregulin and epiregulin, which are crucial in the orchestration of the events leading to ovulation and subsequent development and survival of the CL (Park et al., 2004; Ben-Ami et al., 2006) . In support for the latter action, anti-apoptotic actions of EGF-like molecules, via the activation of EGFR, were described. These studies used IVF-derived human GCs (Ben-Ami et al., 2006) and the authors concluded that EGFR activation is crucial for the survival of the human CL. Interestingly, EGF is a factor, which also targets human oocytes and positively affects human oocyte maturation (Yu et al., 2012) . The activation of the EGFR is linked to a complex signaling cascade, which includes among others the generation of reactive oxygen species (ROS; Finkel, 2011) . Whether this occurs also in ovarian cells is however not known. As recently described, ROS evolved as physiological signaling molecules and as such may also be involved in ovulatory events (Shkolnik et al., 2011; Saller et al., 2012) .
Whether DCN, via its ability to interfere with EGFR signaling, is a potential regulator of ovarian functions is unknown. To explore this point, we studied DCN expression in rhesus monkey and human ovary. We also determined DCN levels in the FF from IVF patients and used luteinized human GCs to explore its potential to act as a signaling molecule and to affect apoptosis.
Materials and Methods
Human GC culture FF, containing human GCs, was obtained from IVF patients stimulated according to routine protocols. The local ethics committee of the University of Munich (LMU) approved the study (project number 323/05) and patients granted written informed consent. Aspirates with cells from two to four patients were pooled for each experiment. For ELISA studies the aspirates from individual patients were pooled. Cells were separated by centrifugation at 560g for 3 min and washed in serum-free Dulbecco's modified eagle's medium (DMEM)/Ham's F-12 (PAA GmbH, Cö lbe, Germany). The supernatant, i.e. FF, was frozen at 2208C until used in DCN ELISA studies. Cells were resuspended in culture medium supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% fetal calf serum (FCS) (all from PAA GmbH), as previously described (Mayerhofer et al., 1992; Mayerhofer et al., 1993; Bulling et al., 2000; Mayerhofer et al., 2006; Saller et al., 2012) . Fresh, uncultured cells (Day 0) and cultured cells were used. The latter were harvested on Days 1 -4 for RT-PCR and western blot studies. Other experiments were performed on Day 2 of culture, unless otherwise indicated. The numbers of replicates are provided for each experiment.
Ovarian samples and immunohistochemistry
Paraffin-embedded ovaries from six adult rhesus monkeys (age 5 -6 years) were the same as used in previous studies (Mayerhofer et al., 2006) . All samples displayed pre-antral and antral follicles (maximum diameter of 3 mm) and three of these contained functional CL. All tissue collections were approved by the Oregon National Primate Research Center Institutional Animal Care and Use Committee. Human ovarian sections were from the tissue archive of the Institute of Anatomy and Cell Biology, Munich. Ovaries (n ¼ 8) contained pre-antral and antral follicles with a maximum diameter of 10 mm. Three functional CL were present in the samples. For immunohistochemistry, 5-mm-thick sections were cut and deparaffinized. Sections were subjected to antigen retrieval by heating in citrate buffer (1.8 mM citric acid, 8.2 mM sodium citrate, pH 6.0) at 908C for 30 min and endogenous peroxidase activity was blocked. Sections were incubated overnight at 48C with a goat anti-human DCN antiserum (1:100; R&D Systems, Wiesbaden-Nordenstadt, Germany), which also recognizes monkey DCN (Adam et al., 2012) followed by a second antibody (biotinylated anti-goat; 1:500; Vector Laboratories, Inc. Burlingame, CA, USA), and avidin -biotin complex peroxidase (ABC, Vector Laboratories). Incubation with normal non-immune serum instead of the specific antiserum, or omission of the primary antiserum, served as controls.
Isolation of RNA and RT-PCR
Total RNA from fresh (Day 0; n ¼ 6) and cultured human GCs at several time points (1, 2, 3 and 4 days after collection; n ¼ 3/time point) was isolated using RNeasy minikit (Qiagen GmbH, Hilden, Germany). Four hundred nanograms of total RNA was subjected to reverse transcription using random hexamer primers and Superscript-RT II (Life Technologies, Karlsruhe, Germany). RT-PCR was performed using oligonucleotide primers for DCN, GFRs and cyclophilin as detailed in a previous study (Adam et al., 2011) . Controls with RNA input instead of cDNA input or without cDNA were performed. Amplified PCR products were separated and visualized by ethidium bromide stained agarose gels. The identities of all PCR products were verified by sequencing (Adam et al., 2011; Saller et al., 2012) .
Gene array of monkey ovarian samples and quantitative real-time RT-PCR
The level of DCN mRNA in macaque CL obtained throughout the luteal phase of the menstrual cycle was determined from a published DNA microarray database (Bogan et al., 2008 (Bogan et al., 2008) . The sequence from the corresponding Affymetrix TM DCN probe set was used to BLAST the human and rhesus macaque genome sequence to ensure its proper annotation.
Following the isolation of RNA from individual CL, cDNA was synthesized and qPCR was performed as previously described (Bogan et al., 2008) . The rhesus macaque DCN and mitochondrial ribosomal protein S10 (MRPS10) DNA sequences served as templates for the design of qPCR primers and TaqMan probes via PrimerExpress software (Applied Biosystems, Foster City, CA, USA). The DCN primer sequences are 5
′ -TGGGCTGGCAGAGCATAAGT-3 ′ (forward) and 5 ′ -CCAGGTGGG CAGAAGTCACT-3 ′ (reverse), whereas the MRPS10 primer sequences are 5
′ -AATGTGCCCAACCTTCATGTC-3 ′ (forward) and 5 ′ -TCCAGG CAAACTGTTCCTTCA-3 ′ (reverse). The DCN probe sequence is 6FAM-5 ′ -CATCCAGGTTGTCTACCTT-3 ′ -MGBNFQ and the MRPS10 probe sequence is VIC-5
′ -TGAAGGCCATGCAGTCTCTCAAGTCC C-3 ′ -MGBNFQ. Primers and probes were purchased from Invitrogen (Carlsbad, CA) and Applied Biosystems, respectively. Target gene concentrations were normalized to MRPS10 levels. Results are given as the mean + SEM of four to eight samples/stage of the luteal phase.
Enzyme-linked immunosorbent assay
To examine DCN in FF, a commercial immunoassay (R&D Systems, GmbH) was used. The assay was performed according to the manufacturer's protocol, as described previously (Adam et al., 2011) . Pooled follicular aspirates of 20 randomly selected IVF patients were examined in duplicates.
Measurements of intracellular Ca 21 levels
Ca 2+ measurements were performed as described previously (Mayerhofer et al., 1992 (Mayerhofer et al., , 1993 Rey-Ares et al., 2007) . In brief, GCs from three different pools of patients (Days 2 and 3) were grown on glass cover slips for 24 h in DMEM/Ham's F-12 supplemented with 10% FCS and 1% penicillin/ streptomycin, loaded with 5 mM fluo-4, acetoxy-methylester (fluo-4 AM, Molecular Probes, Eugene, OR, USA) for 30 min at 378C and 5% CO 2 . Thereafter, cells were washed with FCS-free medium and the cover slip was transferred into a recording chamber mounted on a TCS SP2 confocal microscope (Leica Microsystems, Bensheim, Germany). Fluorescence was monitored at 500 -540 nm (l ex ¼ 488 nm) every 2 s and the intensity was quantified over single cells. To assess whether human GCs respond to DCN, changes of intracellular Ca 2+ were recorded on-line. In pilot experiments, 5 mg/ml of human recombinant (Immundiagnostik AG, Bensheim, Germany) or bovine articular cartilage DCN (Sigma-Aldrich, Munich, Germany) were evaluated. No differences in the ability of the two DCN preparations to mobilize intracellular Ca 2+ were observed, as was described in a previous study (Adam et al., 2011) . Measurements of Ca 2+ levels after adding 5 mg/ml of bovine serum albumin (BSA; pH 7.8; PAA GmbH) were conducted to exclude non-specific protein effects.
Western blot analyses
Western blotting was performed as previously described (Mayerhofer et al., 1999) . In brief, human GCs (n ¼ 3 pools) were cultured on 60-mm dishes (Nunc GmbH & Co. KG, Wiesbaden, Germany) in DMEM/Ham ′ s F-12 medium containing 10% FCS and 1% penicillin/ streptomycin. We performed immunoblots using the same DCN antiserum as for immunohistochemistry. The use of a b-actin antibody (1:5,000, Sigma-Aldrich) allowed us to detect possible differences in loading. Western blot bands were detected with chemiluminescent reagents (SuperSignal w West Femto Maximum Sensitivity Substrate, Pierce, Thermo Scientific, Rockford, IL, USA).
The ability of DCN and EGF to phosphorylate EGFR was studied by western blotting (Adam et al., 2011) . Human GCs were incubated with 5 mg/ml of recombinant bovine DCN and 50 ng/ml of human recombinant EGF (New England Biolabs, Frankfurt, Germany) for 10 min in DMEM/ Ham's F-12 without FCS. To exclude non-specific protein effects, cells were treated with 5 mg/ml of BSA (pH 7.8). In additional controls PBS was added. Immunoblotting was performed using 0.4 mg/ml of rabbit anti-phospho-EGFR solution (1:250; R&D Systems). For control purposes, a monoclonal rabbit anti-human EGFR antibody (1:100; Thermo Fisher Scientific Inc., Fremont, CA, USA) was used. Bands were analyzed densitometrically with ImageJ Software (National Institutes of Health, Bethesda, MD, USA; version 1.40 g) and the results normalized to those obtained for Decorin in the ovary EGFR. Four independent experiments using cells from different patients were evaluated.
Qualitative measurement of ROS and quantification of ROS
The 2-,7-dichlorodihydrofluoresceindiacetate (DCFH 2 -DA) method (Kim et al., 2008 ) was used, as described previously (Saller et al., 2012) . The DCFH 2 -DA dye (Invitrogen, Life Technologies GmbH Karlsruhe, Germany), added at the beginning of the measurements (at 10 mM), is taken up by cells and in the presence of intracellular ROS converted to the highly fluorescent compound DCF (dichlorofluorescein). For qualitative assessment this was monitored using a fluorescence microscope (Zeiss Axioskop FSZ+; Zeiss, Jena, Germany). For quantification purposes of ROS, human GCs were placed in 96-well plates with buffer containing 140 mM NaCl, 3 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM HEPES and 10 mM glucose (pH 7.4). Cells were treated with human recombinant (10, 100 ng/ml and 1, 10 mg/ml) or bovine articular cartilage (1, 5, 10 mM) DCN alone or together with 1 mM N-acetylcystein (NAC; Sigma-Aldrich). For the measurements with DCN, this substance was added 30 min before starting ROS measurements and incubated at 378C. For each treatment, eight replicate measurements/treatment group were performed. Fluorescence was measured at 485 nm excitation/520 nm emission monitored by a fluorimeter at RT (Fluostar, BMG Labtech GmbH, Offenburg, Germany). The differences between the values determined after 2 h, when the experiments were terminated, were statistically analyzed. Fluorescence intensities shown were normalized to untreated controls. For all ROS experiments, GCs on Day 2 of culture were used and experiments were repeated two to three times with cells from different patients.
Caspase assay
The activities of the effector caspases 3/7 were determined following exposure of human GCs to DCN or EGF (Saller et al., 2010) . Cells were cultured for 2 or 5 days (three experiments using cells from different patients/time point) and subsequently treated with DCN (5 mg/ml) and EGF (50 ng/ml) for 24 h. Staurosporine (1 mM; Sigma-Aldrich) was used as a positive control. Hundred microlitres of CaspaseGlow 3/7 reagent (Promega, Mannheim, Germany) were added to each well of a whitewalled 96-well microplate containing 100 ml of untreated or stimulated cells. Contents of the plate were mixed on a plate shaker at 500 cycles per minute for 30 s and incubated for 1 h afterwards. The luminescence of each sample was measured in a plate-reading luminometer (Fluostar).
Data analysis and statistics
Data were analyzed using PRISM 4.0 (GraphPad Software, Inc., San Diego, CA). T-test or one-way ANOVA tests were performed (gene expression, qPCR, caspase assay; ROS). Differences between the groups were evaluated with a post hoc test (Newman-Keuls).
Results

DCN expression in the non-human primate and human ovary
Immunohistochemistry revealed an almost identical DCN staining pattern in all sections of adult rhesus monkey and human ovaries (Fig. 1) . In both species, DCN staining was associated with the stromal connective tissue (Fig. 1A and D) and the theca layers of follicles (Fig. 1D) . GCs within all classes of pre-antral and antral follicles were immuno-negative for DCN (Fig. 1A, B and D) , including large antral follicles within human ovarian follicles (diameters up to 10 mm) and the equivalent stage in monkey sections (diameters up to 3 mm). DCN staining was readily found in luteal cells and connective tissue cells of all CL present in the sections examined (Fig. 1B, C, E and F). In human CL, DCN was localized to small areas between luteal cells as well as in the connective tissue (Fig. 1F) . DCN was furthermore detected in the cytoplasm of some monkey luteal cells (Fig. 1C) . Controls with non-immune serum (data not shown) and omission of primary antiserum were negative (Fig. 1A and D inserts) .
DCN was readily detected in the FF from 20 patients undergoing IVF. ELISA measurements showed that the DCN levels ranged from 6.7 to 23.6 ng/ml with a mean of 12.9 + 4.5 (standard deviation; Fig. 2A ). Freshly isolated luteinizing GCs expressed DCN, as shown by RT-PCR in a total of six different pools of GCs (Fig. 3A) .
The analysis of gene expression data revealed overall high levels of DCN mRNA in monkey CL samples obtained from different stages of the natural luteal phase (data not shown). The data also revealed that DCN mRNA levels more than doubled (P , 0.05) in CL undergoing regression at the end of the luteal phase (late stage CL) relative to its levels within CL from the developing (early stage CL) and functional (mid-stage CL) points of the luteal phase. This pattern was confirmed by qPCR (P , 0.05; Fig. 2B ). The structural partner molecule of DCN, collagen type I, was not increased in parallel in the late stage CL, but rather a significant drop was observed at the very late stage (data not shown). Moreover, significant but constitutive levels of DCN mRNA are present in the naturally selected rhesus macaque follicle (whole follicles including granulosa and theca compartments) prior to and after an ovulatory stimulus, as determined by a separate DNA microarray study (Xu et al., 2011 ; data not shown).
DCN expression was noted in human ovary (data not shown), as well as freshly isolated, luteinizing GCs (Day 0) and luteinized GCs cultured for 1-4 days ( Fig. 3A and B) . Western blot analyses of several batches (3 -6 each) of cultured human GCs (Fig. 3C ) also showed DCN protein expression.
DCN actions in human luteinized GCs
The addition of DCN (5 and 10 mg/ml) to human GCs after 2 or 3 days of culture induced, within seconds, transient elevations of intracellular Ca 2+ , which is suggestive of interaction with and activation of GFRs ( Fig. 1A and B) . Both human recombinant and bovine DCN were equally effective. BSA (5 mg/ml), which served as a negative control to exclude non-specific protein effects, did not alter intracellular Ca 2+ levels (Fig. 4B) . The experiment was repeated four times using different batches of pooled human GCs, consisting of at least 100 cells. The effect of DCN was found in all experiments, yet the magnitude and onset of individual responses of cultured GCs varied somewhat as seen in Fig. 4A . The addition of 1 and 10 mg/ml of DCN to cultured GCs generated ROS (Fig. 4C-E) , an effect that was observed within minutes and was statistically significant (P , 0.05) after 2 h when the experiments were terminated. The addition of the antioxidant NAC inhibited the DCN-dependent increase in ROS levels. The magnitude of ROS generation increased with higher concentrations of DCN. Lower doses of DCN (10 -100 ng/ml) did not significantly increase ROS within 2 h (not shown).
To examine whether DCN could act via GFRs expressed by GCs, we screened GCs for GFRs by RT-PCR, with the DNA product identity being verified by sequencing (Fig. 5A and data not shown) . Cultured human GCs (Days 1-4 in the culture) express several GFRs, which are known to be partners of DCN in other tissues. They include receptors of the EGFR family, namely EGFR, ErbB2 Representative results from the qualitative assessment of ROS production in GCs prior to (0 min) and 30 min after the addition of DCN (10 mg/ ml) and 30 min after the addition of DCN and NAC (1 mM). Increased fluorescence signals indicate the generation of ROS. Bar 30 mm. (D) Quantitative ROS-measurements using human recombinant DCN (10 mg/ml) and NAC (1 mM). Values shown are means + SD of three independent measurements using eight replicates/group each. Data are normalized to untreated values (control; co) and represent arbitrary fluorescence intensities. DCN induced a significant increase in ROS levels at 2 h compared with control and NAC plus DCN groups (P , 0.001). (E) Results of quantitative ROS measurements using two concentrations of human recombinant DCN (1 mg/ml and 10 mg/ml). Results are given as the mean + SD of one experiment using eight replicates/group. Values shown were normalized to untreated values (control; co) and represent arbitrary fluorescence intensities. Values observed after 2 h, when the experiments were terminated, are as follows: 1.05 + 0.02 for 1 mg/ml of DCN and 1.5 + 0.03 for 10 mg/ml of DCN. The evaluation of values at 2 h showed that the treatment groups with 1 and 10 mg/ml of DCN were significantly different from controls (P , 0.001).
(v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ErbB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3) and ErbB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4; Fig. 5A ). In addition, receptors for hepatocyte GF (HGFR; Met-receptor) and platelet-derived GF (PDGFR-a and -b) were detected (data not shown).
To test whether EGFR is among the receptors targeted by DCN in the ovary, DCN (5 mg/ml) was added to human GCs for 10 min and the phosphorylation of the EGFR was determined by western blotting (Fig. 5B) . The results of four independent experiments, using cells from different patients, indicate that EGFR phosphorylation occurred within 10 min upon addition of DCN. The normalization of phosphorylated EGFR to total EGFR levels revealed an increase of 1.4-4.6-fold following DCN treatment versus untreated controls. Similar responses were observed upon addition of 50 ng/ml of EGF (1.2-4.1-fold). The addition of BSA (5 mg/ml) did not cause EGFR phosphorylation and therefore, a non-specific protein effect can be excluded.
Finally, we tested whether exogenous DCN or EGF can affect apoptotic events in cultured GCs (Fig. 5C ). The treatment of human GCs (Day 2 of culture; 3 experiments) with EGF (50 ng/ml) or DCN (5 mg/ml) for 24 h led to variable results but did not robustly affect caspase 3/7 activity levels, which are a measure of apoptosis. However, when GCs were tested on Day 5 following a 24 h treatment period, DCN and EGF significantly reduced caspase 3/7 activity levels in three independent experiments (Fig. 5C ). Staurosporine (1 mM), used as positive control, strongly induced caspase 3/7 activity (data not shown).
Discussion
The results of this study revealed that DCN is a member of the ECM within the primate ovary, where it is found in stromal, follicular thecal and luteal tissue. DCN is absent from follicular (non-luteinized) GCs. In the CL it is localized to small aggregates between granulosa lutein cells and to the cytoplasm of some luteal cells, and is found in the connective tissue. Lastly, DCN is present in human FF and freshly isolated, luteinizing human GCs obtained from IVF patients. Hence, DCN is induced in GCs around ovulation and its levels furthermore increase in the late CL at the end of the menstrual cycle.
The study also provides insight into a possible functional role of DCN in the ovary. Using cultured luteinized human GCs as a test system, DCN behaved as a paracrine factor. DCN increased intracellular Ca 2+ levels, caused the generation of ROS and reduced apoptosis. These actions are most likely due to the ability of DCN to target GFRs, including EGFR and others. Given the widespread distribution of DCN in the primate ovary and distinct changes of its levels during the ovarian cycle, the results suggest that DCN is a hitherto unknown factor involved in the regulation of important ovarian functions.
The composition of the ECM in the human or non-human primate ovary, and especially the CL, is not well defined. Aggregates of interstitial ECM between luteal cells in the human CL were reported in a previous study (Irving-Rodgers et al., 2006) with the ECM components laminin and collagen type IV being synthesized by human luteal cells. The synthesis of DCN by primate luteal cells was clearly shown by immunohistochemistry and by cellular assays in the present study. Some differences between monkey and human CL staining became apparent. In macaques, DCN stained the cytoplasm of luteal cells and outlined their circumference, indicative of synthesis and secretion. Cytoplasmic DCN in human luteal cells was not evident, possibly due to differences in fixation; but its synthesis by freshly isolated luteinizing human GCs and cultured luteinized GCs was unequivocally shown. Thus, periovulatory events led to an induction of DCN expression by GCs. Furthermore, FF from IVF patients contained DCN. It is (2) and BSA do not. Results using an antibody recognizing non-phosphorylated EGFR in the same samples are shown in the middle panel and were used to normalize the results. In the densitometric evaluation of four western blot experiments (bottom panel) EGF and DCN robustly phosphorylate EGFR to the same extend (mean + SD). (C) The result of a representative caspase 3/7 activity assay. Both EGF and DCN significantly reduced the levels after 24 h (P , 0.05; mean + SEM; 6 wells/group). Results are expressed in relative luminescence units (RLU). Two additional experiments yielded similar results.
Decorin in the ovary possible that luteinizing GCs are responsible for this production, but a contribution from the theca cells, which strongly stain for DCN, is possible as well.
In general, the ECM actively participates in the regulation of important processes, including cell migration, proliferation and differentiation. The capacity of ECM to affect cellular function stems from its ability to serve as a storage compartment for GFs and to affect GFR activities. DCN, known to stabilize collagen fibrils of collagen type I , can also store GFs and furthermore activate/interfere with multiple GFR signaling systems. A number of GFR partners for DCN are now known and include EGFR (Schaefer and Iozzo, 2008) , as well as insulin-like GFR-1 (IGF-1R; Schaefer and Iozzo, 2008) , vascular endothelial GFR (Iacob et al., 2008) , PDGFR-a/-b (Nili et al., 2003) and HGFR (Goldoni et al., 2009) .
We explored the possibility that DCN may activate ovarian GFR signaling systems. Most human ovarian cells (theca and stromal cells, oocytes) are not available for such experiments. GCs, which correspond to periovulatory GCs and granulosa-derived luteal cells of the CL are available and were studied. GCs are a relevant model because they express several GFRs (Kwintkiewicz and Giudice, 2009; Karakida et al., 2011 ; results of the present study). Furthermore, DCN in FF and DCN expression by GCs undergoing luteinzation, show that the potential ligand for all these GFR is present as well.
The observed actions of DCN, namely transient increases in Ca   2+ and ROS generation, are indicative of GFR activation by DCN (Iozzo and Schaefer, 2010; Finkel 2011) . However, it is an intrinsic property of DCN to bind to several GFRs albeit with different binding affinities (Iozzo and Schaefer, 2010) . Thus, the expression pattern of GFRs, their abundance and the local concentration of DCN will determine whether and how DCN acts. With regard to the ovary, many details thus remain to be studied but the actions of DCN observed in GCs demonstrate that DCN is able to act as a signaling molecule. Our results furthermore indicate that the EGFR is one of the GFRs directly targeted by DCN in human GCs, as shown directly by rapid phosphorylation of EGFR upon addition of DCN. Phosphorylation is an early step in EGFR signaling and this action of DCN is similar to that described in previous studies with EGFR-expressing cells (Iozzo et al., 1999; Csordas et al., 2000; Zhu et al., 2005; Adam et al., 2011) . We studied EGFR activation, because in the context of ovarian physiology, especially in non-primate species, EGFR signaling plays an important role in ovulation (Park et al., 2004 , Conti et al., 2006 , Hsieh et al., 2011 . Recent studies on monkeys (Xu et al., 2011; Peluffo et al., 2012) and women (Inoue et al., 2009) suggest that the importance of EGF and EGF-like molecules likely extends to primates (Khan et al., 2005; Ben-Ami et al., 2006; Karakida et al., 2011; Xu et al., 2011; Humaidan et al., 2011) . It is also noteworthy that not only human GCs may be targeted by GFs (Ben-Ami et al., 2006) , but also human oocytes and cumulus cells, which express EGFR and IGF-1R, i.e. known targets for DCN (Yu et al., 2012) .
The activation of EGFR, and also of other GFRs, leads to increased production of ROS (Finkel, 2011) , which also occurred following GC treatment with DCN. This aspect of DCN function is of interest in light of the evolving role of ROS in ovarian physiology (Saller et al., 2012) . At least in rodents, a significant contribution of ROS to the ovulatory process was recently shown (Shkolnik et al., 2011) .
A role of EGFR signaling in human CL may be to block apoptosis of luteal cells, according to a study, in which such actions promoted the survival of cultured human GCs (Ben-Ami et al., 2006) . In line with this study, we also found that EGF significantly lowered caspase activity in GC cultures treated on Day 5 after isolation, while we did not observe such an effect in our cultures on Day 2 after isolation. Importantly, DCN mimicked the EGF actions and had a significant inhibitory effect on caspase activity on Day 5. The similar actions of EGF and of DCN in our study imply that DCN acts, at least in part via EGFR, to affect caspases and presumably apoptosis. Yet, because DCN can also interact with other GFRs expressed by GCs, the involvement of other GFRs must be considered. Furthermore, human GCs may also die by non-apoptotic pathways (Bulling et al., 2000) , for which caspase 3/7 activation may not be a relevant measure.
Our analysis of DCN mRNA in naturally selected follicles and CL of rhesus macaques documented high levels of DCN around ovulation throughout the life of the CL. Towards the end of the luteal lifespan DCN is significantly increased, before returning to baseline levels at the time of menses. Since collagen type I levels did not increase in parallel with DCN, it is unlikely that this rise is related to structural properties of DCN in the ECM. Given the ability of DCN to store and thus lower available GF levels, the increase in DCN in the CL could be interpreted as a timed event, which may be involved in the demise of the CL by limiting important paracrine signaling events. Downregulation of GFRs, namely EGFRs, is another mode of DCN action that was described to occur after an initial activation (Csordas et al., 2000; Zhu et al., 2005) . Whether this occurs as a response to high levels of DCN in the CL remains to be shown.
How DCN is regulated in the ovary, e.g. how it is induced in GCs during ovulation and increased in the regressing CL is unknown. Hormonal signals might be involved, but in other organs there is only evidence for DCN regulation by local factors, including products of immune cells, e.g. mast cell-derived tryptase and tumor necrosis factor alpha (Adam et al., 2011 (Adam et al., , 2012 , thrombin (Ivey and Little, 2008) , interleukin-1 (IL-1) and IL-4 and others (Pulkkinen et al., 1992; Mauviel et al., 1995; Wegrowski et al., 1995) .
In summary, the results identify DCN as part of the ovarian ECM in the ovarian stroma, follicular theca cells and luteal cells. Moreover, DCN is present in the FF of ovulatory follicles. Distinct changes of DCN expression are associated with ovulation and the demise of the CL. In human GCs, DCN can act as a paracrine signaling factor due to its ability to interfere with GF/GFR systems. Our study thus raises the possibility that DCN is a local regulator of folliculogenesis, ovulation and the functional lifespan of the CL in primates. 
